Use of Faecalibacterium Prausnitzii Htf-f (DSM 26943) to Suppress Inflammation

• US 20160000838A1
• Filed: 03/05/2014
• Published: 01/07/2016
• Est. Priority Date: 03/05/2013
• Status: Abandoned Application

• Current Assignee: Academisch Ziekenhuis Groningen, Rijksuniversiteit Groningen, The University Court of the University of Aberdeen, Wageningen University
• Original Assignee: Academisch Ziekenhuis Groningen, Rijksuniversiteit Groningen, The University Court of the University of Aberdeen, Wageningen University
• Inventors: HARMSEN, Hermanus Josef Martinus, KHAN, Muhammad Tanweer, WELLS, Jeremy, ROSSI, Oriana, FLINT, Harry James, DUNCAN, Sylvia Helen
• Application Number:
  US14/772,519
• Publication Number:
  US 20160000838A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A23K 10/16 Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions A23K10/12 takes precedence
• CPC Class Codes: A23K 10/18 of live microorganisms
• CPC Class Codes: A23K 50/40 for carnivorous animals, e.g. cats or dogs
• CPC Class Codes: A23L 29/065 Microorganisms addition of bacteria for nutritional purposes A23L33/135
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23L 33/175 Amino acids
• CPC Class Codes: A23L 33/21 Addition of substantially indigestible substances, e.g. dietary fibres
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2250/0616 Cysteine
• CPC Class Codes: A23V 2250/206 Bacterial extracts
• CPC Class Codes: A23V 2250/5062 Inulin
• CPC Class Codes: A23V 2250/5072 Pectine, pectinate
• CPC Class Codes: A23V 2250/7044 Vitamin B2
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.

Claims

1. A pharmaceutical, neutraceutical or food composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (deposited with the DSMZ on Mar. 1, 2013 under the accession number DSM 26943), and an acceptable carrier, diluent or excipient.

2. Composition according to claim 1, comprising viable cells of Faecalibacterium prausnitzii strain HTF-F (DSM 26943).

3. Composition according to claim 1, comprising non-viable cells of Faecalibacterium prausnitzii strain HTF-F (DSM 26943).

4. Composition according to any one of claims 1-3, further comprising one or more prebiotics, preferably oligosaccharides, more preferably fructooligosaccharides, pectins and/or inulin.

5. Composition according to any one of claims 1-4, further comprising one or more probiotic bacteria, preferably selected from the group consisting of Bifidobacterium, Lactobacillus, Streptococcus and Saccharomyces and mixtures thereof.

6. Composition according to any one of claims 1-5, being a food composition, food supplement or neutraceutical.

7. Composition according to any one of claims 1-5, being a pharmaceutical composition, preferably formulated in an orally ingestible form, preferably in the form of a capsule, microcapsule, tablet, granule, powder, troche, pill, suspension or syrup.

8. F. prausnitzii strain HTF-F (DSM 26943) for use as a medicament.

9. F. prausnitzii strain HTF-F (DSM 26943) for use in a method for treating or preventing symptoms associated with an inflammatory disorder and/or microbiota disbalance of the gastrointestinal tract of a mammalian subject.

10. F. prausnitzii strain HTF-F for use according to claim 9, wherein said subject is a human.

11. F. prausnitzii strain HTF-F for use according to claim 9, wherein said subject is a domestic animal or an agricultural animal.

12. F. prausnitzii strain HTF-F for use according to any one of claims 8-11, wherein said bacterium is formulated to be administered to a subject in a therapeutically effective amount, preferably wherein the therapeutically effective amount of the bacterium is about 10exp6 to 10exp11 CFU/day.

13. F. prausnitzii strain HTF-F for use according to any one of claims 8-12 wherein said gastrointestinal disorder is selected from the group consisting of inflammatory bowel disease, Crohn'"'"'s disease, irritable bowel syndrome, coeliac disease, infectious colitis, ulcerative colitis, and any combination thereof.

14. A method for producing an anti-inflammatory composition, comprising the steps of

a) harvesting living cells of Faecalibacterium prausnitzii strain HTF-F (DSM 26943) and resuspending the cells in a suitable buffer, preferably PBS;

b) vortexing the resuspended cells for at least 3 minutes allowing the cell-bound extracellular polymeric matrix (EPM) to dissolve in the buffer;

c) pelleting the cells by centrifugation and harvesting the supernatant

d) adding about 4 volumes of ice-cold ethanol to the supernatant to precipitate the EPM;

e) washing the precipitated EPM with ethanol;

f) optionally followed by lyophilization.

15. A synbiotic composition comprising living cells of Faecalibacterium prausnitzii strain HTF-F (DSM 26943) formulated with (i) riboflavin, riboflavin phosphate or a physiologically acceptable salt thereof in an amount of at least 0.05% based on the total dry weight of the composition, and (ii) cysteine, preferably present in an amount of at least 0.05% based on the total dry weight of the composition.

16. Synbiotic composition according to claim 15, further comprising inulin or inulin-type fructo-oligosaccharides, pectin preferably in an amount of 2-10% based on the total dry weight of the composition.

17. Use of Faecalibacterium prausnitzii strain HTF-F (DSM 26943) for the production of an anti-inflammatory composition.